GATAD2A Recombinant Monoclonal Antibody

GATAD2A, also known as transcriptional repressor p66-alpha, serves as a critical component of the NuRD (nucleosome remodeling and deacetylase) chromatin remodeling complex. This protein plays essential roles in transcriptional regulation, chromatin organization, and cellular differentiation processes, making it a significant target for researchers investigating epigenetic mechanisms, developmental biology, and cancer progression.

This recombinant monoclonal antibody, generated from clone 12B10, offers the reproducibility and consistency that demanding experimental workflows require. Because the antibody sequence is defined and produced recombinantly in rabbit host cells, you can expect reliable performance across experiments and between lots, eliminating the variability concerns often associated with traditional hybridoma-derived antibodies. The affinity-chromatography purification ensures high specificity for your GATAD2A detection needs.

Validation studies demonstrate robust performance across multiple applications. Western blot analysis detects a clean band at the predicted 68 kDa molecular weight in human K562 and Jurkat cell lysates, as well as mouse NIH/3T3 cells, confirming cross-species reactivity with both human and mouse samples. Immunohistochemistry staining in paraffin-embedded human glioma tissue reveals clear nuclear localization patterns consistent with GATAD2A's function as a transcriptional regulator. Immunofluorescence studies in MCF-7 cells further demonstrate nuclear staining, while flow cytometry analysis in Jurkat cells shows distinct positive population shifts compared to isotype controls.

This versatility across Western blot, immunohistochemistry, immunofluorescence, and flow cytometry applications provides flexibility for researchers studying NuRD complex function, chromatin remodeling mechanisms, or exploring GATAD2A's emerging roles in cancer biology and stem cell differentiation.